NASDAQ · SDGR

Schrodinger, Inc.

$14.97 -$0.16 (-1.06%) 1D After hours

Key Metrics

$1.12B
Market cap
P/E · TTM
$254.91M
Revenue · TTM
−$103.48M
Net income
EPS · TTM $-1.42
Dividend yield
Free cash flow −$148.35M
Beta · 1Y 1.70
EBITDA · TTM −$96.26M
Gross margin 55.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 5
    The stock moved -9.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 5
  • Feb 11
    The stock moved -12.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.12B
Enterprise value
Shares outstanding74.7M
52-wk range$10.95 – $23.02
Avg volume · 20D911.1K
Net cash
Book value / share$4.29
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Schrodinger, Inc.
IPO dateFeb 6, 2020
Employees850

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S4.39
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 55.3%
Operating -40.1%
Net -40.6%
FCF -58.2%
ROE / ROIC -28.2% · 121.2%

Financial Health

Current ratio2.74
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$294.42M

Cash Flow · TTM

Operating CF −$145.00M
Capex −$3.35M
Free cash flow −$148.35M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

1.0
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings